E37: TRACE-RA Atorvastatin for Primary Prevention of CVD in RA

E17: Steroids and the Risk of Scleroderma Renal Crisis: Short but impactful paper this week on the association between steroids and scleroderma renal crisis. Find the original paper here. by The Evidence Based Rheumatology Podcast

11 min listen

E6: Methylprednisolone and Cyclophosphamide, Alone or in Combinatinon, for Lupus Nephritis: Welcome back! Before we talk about cellcept for lupus nephritis, I decided we should flash back to 1996 and discuss one of the early trials that brought us cyclophosphamide. It's a quick discussion that will help set us up nicely for ALMS this Sunday. ... by The Evidence Based Rheumatology Podcast

9 min listen

E13: Withdrawing HCQ in SLE: Short podcast today on an old RCT addressing the utility of hydroxychloroquine (plaquenil) in lupus. It's an oldie but goodie and one that I enjoyed talking about. by The Evidence Based Rheumatology Podcast

11 min listen

E22: Ustekinumab for Giant Cell Arteritis: Quick episode today on a small prospective trial on ustekinumab for giant cell arteritis. Papers can all be found here! by The Evidence Based Rheumatology Podcast

9 min listen

E9: Rituximab in Myositis - The RIM Trial: This week we'll discuss a randomized controlled-ish trial, the RIM study. It pits rituximab against placebo as well as... rituximab? We'll talk about how their design convincingly demonstrated that ritixan does not have a benefit over placebo for 8 week... by The Evidence Based Rheumatology Podcast

17 min listen

E14: Cardiovascular Safety of Febuxostat: Today we'll discuss an important trial on febuxostat (ulloric), which raises important concerns about its safety from a cardiovascular perspective. Be sure to tune in to the #RheumJC discussion that will be happening this Thursday! by The Evidence Based Rheumatology Podcast

14 min listen

E46: Rituximab in Lupus: Finally got around to tackling rituximab in SLE. This is a tough topic: lots of people feel passionately one way or another, flawed observational data supports its use, flawed RCTs did not find significant benefit, and patients are left in the lurch. I... by The Evidence Based Rheumatology Podcast

22 min listen

E16: Tocilizumab in Giant-Cell Arteritis - GIACTA: Getting back to our usual format, this week we'll discuss the GIACTA trial, which compared various schedules of tocilizumab to various schedules of placebo and prednisone. It's an important trial that has changed the face of GCA and will be a refreshing... by The Evidence Based Rheumatology Podcast

16 min listen

E8: Mepolizumab or Placebo for EGPA: This week we'll discuss a recent trial on mepolizumab - and IL-5 inhibitor - for eosinophilic granulomatosis with polyangiitits. Find the paper here and be sure to follow us on twitter @JBRheum! by The Evidence Based Rheumatology Podcast

14 min listen

E12: ACR 2015 Workforce Study - the Rheumageddon!: This week we'll discuss the recently published ACR Workforce Study, which estimates a substantial deficit in the workforce by 2030. We'll consider how dire the situation actually is - checkout the paper itself here. by The Evidence Based Rheumatology Podcast

15 min listen

E10: Abatacept in RA-ILD: Quick podcast tonight reflecting the Rheumatology Journal Club (@RheumJC) discussion! I joined as they discussed the use of abatacept in patients with rheumatoid arthritis who develop ILD. It's our first observational trial, so it's ripe for critique! F... by The Evidence Based Rheumatology Podcast

13 min listen

E92: Are muscle symptoms from statins imaginary?: Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! Paper: https://www.thelancet.com/arti... by The Evidence Based Rheumatology Podcast

11 min listen

E44: SELECT-COMPARE Upadacitinib (JAKi) for Rheumatoid Arthritis: Finally got around to tackling the JAKi this week. I decided to focus on SELECT-COMPARE, which pitted upadacitinib (selective JAK1 inhibitor) against adalimumab and placebo. I briefly discuss other JAKs and my thoughts on the future of this area. Get t... by The Evidence Based Rheumatology Podcast

10 min listen

E26: Housekeeping 1: Every 25 episodes I'd like to step back and touch base about where the podcast is headed. Thanks to everyone who has been listening! Apologies for nothing exciting or useful this week. by The Evidence Based Rheumatology Podcast

4 min listen

E7: The ALMS Trial - MMF vs CYC for Lupus Nephritis: Today we'll be discussing the ALMS trial, which pitted cellcept against cyclophosphamide. It's a good trial that has had profound influences on our practice and well worth a read. Access the paper itself here. by The Evidence Based Rheumatology Podcast

10 min listen

E25: MAINRITSAN 2 - Fixed vs. Tailored Rituxan for AAV: Interesting trial this week evaluating a fixed schedule of rituximab vs. a tailored approach to therapy. See you all at ACR this week! by The Evidence Based Rheumatology Podcast

12 min listen

E42: SENSCIS - Nintedanib for Systemic Sclerosis ILD: This week I'll discuss an important paper in systemic sclerosis, the recent SENSCIS trial that compared 150mg nitedanib to placebo. I wind up coming down pretty hard on this drug; I think it's hype has vastly outpaced its utility. Get the paper itself a... by The Evidence Based Rheumatology Podcast

16 min listen

E45: TNF or TCZ or ABA or RTX: Real World Data for RA: This week I tackle an interesting cohort study that Jack Cush (@RheumNow) mentioned in his podcast. It's a nice opportunity to discuss bDMARDs in the "real world" (AKA Sweden). Follow me @ebrheum and let me know what you think of the episode! by The Evidence Based Rheumatology Podcast

15 min listen

E19: Clinical Utility of a Positive ANA: Quick podcast this week on the utility of an ANA. It's a frequent reason for referral (17% in this series) to rheumatology offices and this is a useful paper for context. Find the paper itself here. by The Evidence Based Rheumatology Podcast

8 min listen

E54: Rheum4Debate - Triple Tx is 1st Line in RA w/No Response to MTX: Happy New Year! This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line." Please be sure to VOTE AGAIN on twitter (@ebrheum) a... by The Evidence Based Rheumatology Podcast

17 min listen

E36: Baricitinib for SLE: This week I discuss the phase 2 trial on baricitinib in SLE. Though it's early times (and the total flop of rituxan in ME/CFS recently can attest to this), this was a large phase 2 and I'm hopeful it carries through to the ongoing phase 3 trials. Follo... by The Evidence Based Rheumatology Podcast

14 min listen

E31: SEAM and MIPA Trials: MTX vs. ETN for Psoriatic Arthritis: This week we tackle two RCTs and try to figure out what to do with etanercept, methotrexate, and placebo (or the lack thereof). Good opportunity for jumping into more PsA trials in the near future - lots of IL-somethings to talk about! Remember to foll... by The Evidence Based Rheumatology Podcast

13 min listen

E23: Stress Related Disorders and Subsequent Autoimmune Disease: Great article this week on stress related disorders and their relationship with subsequent autoimmune disease. One of my favorite recent papers from my least favorite way to do a study! Remember, all my articles can be found here! by The Evidence Based Rheumatology Podcast

18 min listen

E15: The Ribosomal P Isn't Useful in NPSLE by The Evidence Based Rheumatology Podcast

17 min listen

E28: Nurse Run Treat to Target vs. Usual Care? in Gout: Interesting trial this week pitting an elaborate nurse led group against suboptimal usual care. Suboptimal usual care lost pretty badly, but what to make of this? And does it support the rheumatologist side of the treat to target controversy? Listen t... by The Evidence Based Rheumatology Podcast

15 min listen

E66: MRI to Diagnose PMR: Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message. Also, check out the "2-5-10" rule that... by The Evidence Based Rheumatology Podcast

14 min listen

E55: Anifrolumab for SLE (TULIP 1&2): This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE. Great to see a new drug in this disease state; interesting to think through how these trials played out. Get the papers and the pod at eb... by The Evidence Based Rheumatology Podcast

18 min listen

E37: TRACE-RA Atorvastatin for Primary Prevention of CVD in RA: This week I pair the recently published TRACE-RA trial assessing the efficacy of atorvastatin in primary prevention of cardiovascular disease. It offered a great opportunity to also go after the recent Nature publication "Scientists rise up against stati... by The Evidence Based Rheumatology Podcast

18 min listen

E79: Vasculitis Guidelines E5 - GCA with Dr. Mehrdad Maz: On today's episode I discuss GCA with Dr. Mehrdad Maz. He is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section and served on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. We... by The Evidence Based Rheumatology Podcast

27 min listen

E52: HOPE RCT - Prednisone for OA of the Hand: Surprising RCT this week discussing the HOPE trial, which pitted 10mg prednisone against placebo for inflammatory hand OA. I do think this will change my practice, but in a far narrower sense than the headline would suggest. Check it out and find all my ... by The Evidence Based Rheumatology Podcast

9 min listen

Discover this podcast and so much more

E37: TRACE-RA Atorvastatin for Primary Prevention of CVD in RA

Description

Titles in the series (87)

More Episodes from The Evidence Based Rheumatology Podcast

Related podcast episodes